DexCom (DXCM) Tops Q4 EPS by 41c, Revenues Beat; Offers FY20 Revenue Guidance

DexCom (NASDAQ: DXCM) reported Q4 EPS of $1.15, $0.41 better than the analyst estimate of $0.74. Revenue for the quarter came in at $462.8 million versus the consensus estimate of $442.38 million.

Fourth Quarter 2019 Highlights:

• Revenue grew 37% versus the same quarter of the prior year to $462.8 million
• U.S. revenue growth of 34% and international revenue growth of 52%
• GAAP operating income of $101.5 million or 21.9% of revenue. Non-GAAP operating income* of $103.6 million or 22.4% of revenue
• Commenced launch of G6 into Medicare

“Dexcom sustained its revenue growth momentum in 2019, exceeding 40% growth for the second consecutive year and driving our first full year of GAAP profitability,” said Kevin Sayer, Dexcom’s Chairman, President and CEO. “We have taken significant steps to prepare the business for long-term growth and believe we are well-positioned as we enter 2020.”

GUIDANCE:

DexCom sees FY2020 revenue of $1.725-1.775 billion, versus the consensus of $1.77 billion.

For earnings history and earnings-related data on DexCom (DXCM) click here.

You May Also Be Interested In

• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
• Angi Inc. names new chief accounting officer after resignation
• Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance